文献速递肝胆胰外科

ALPPS与门静脉栓塞在肝炎相关肝细胞癌中的应用比较

ALPPS Versus Portal Vein Embolization for Hepatitis-related Hepatocellular Carcinoma: A Changing Paradigm in Modulation of Future Liver Remnant Before Major Hepatectomy.
PubMed 文献 · Ann Surg · 2021-01-01

该研究比较了ALPPS与门静脉栓塞(PVE)在肝炎相关肝细胞癌(HCC)患者中调节未来肝残体(FLR)的短期和长期结局。结果显示ALPPS组切除率显著高于PVE组(97.8% vs 67.7%,P<0.001),而两组并发症、死亡率及5年总生存率无显著差异。

要点

  • ALPPS在肝炎相关HCC中切除率高于PVE(97.8% vs 67.7%)。
  • ALPPS与PVE的并发症和死亡率无显著差异。
  • 两组5年总生存率无显著差异(46.8% vs 64.1%)。

核心结论

  • ALPPS在肝炎相关HCC中具有更高的切除率,且短期和长期肿瘤学结局与PVE相当。

研究设计与样本

  • 回顾性比较研究,纳入2002至2018年148例HCC患者(乙肝136例,92.0%),其中ALPPS组46例,PVE组102例。

主要发现

  • ALPPS组切除率为97.8%,PVE组为67.7%(P<0.001)。
  • ALPPS在6天内使FLR绝对体积增加48.8%,FLR占估计全肝体积比增加12.8%。
  • ALPPS与PVE的并发症发生率分别为20.7%和30.4%(P=0.159),死亡率分别为6.5%和5.8%(P=1.000)。
  • ALPPS与PVE的5年总生存率分别为46.8%和64.1%(P=0.234)。
  • ALPPS、PVE和直接肝切除组间PD-1、VEGF和AFP表达无差异。

关键数值与推荐

  • 慢性肝炎和术中吲哚菁绿清除率≤39.5%有利于ALPPS后FLR充分增生。

临床怎么用

  • 对于肝炎相关HCC需行大范围肝切除且FLR不足者,ALPPS可提高切除率且安全性与PVE相当。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to evaluate the short- and long-term outcome of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) for hepatitis-related hepatocellular carcinoma (HCC). SUMMARY BACKGROUND DATA: ALPPS has been advocated for future liver remnant (FLR) augmentation in liver metastasis or noncirrhotic liver tumors in recent years. Data on the effect of ALPPS in chronic hepatitis or cirrhosis-related HCC remained scarce. METHODS: Data for clinicopathological details, portal hemodynamics, and oncological outcome were reviewed for ALPPS and compared with portal vein embolization (PVE). Tumor immunohistochemistry for PD-1, VEGF, and AFP was evaluated in ALPPS and compared with PVE and upfront hepatectomy (UH). RESULTS: From 2002 to 2018, 148 patients with HCC (hepatitis B: n = 136, 92.0%) underwent FLR modulation (ALPPS, n = 46; PVE: n = 102). One patient with ALPPS and 33 patients with PVE failed to proceed to resection (resection rate: 97.8% vs 67.7%, P < 0.001). Among those who had resections, 65 patients (56.5%) had cirrhosis. ALPPS induced absolute FLR volume increment by 48.8%, or FLR estimated total liver volume ratio by 12.8% over 6 days. No difference in morbidity (20.7% vs 30.4%, P = 0.159) and mortality (6.5% vs 5.8%, P = 1.000) with PVE was observed. Chronic hepatitis and intraoperative indocyanine green clearance rate ≤39.5% favored adequate FLR hypertrophy in ALPPS. Five-year overall survival for ALPPS and PVE was 46.8% and 64.1% (P = 0.234). Tumor immunohistochemical staining showed no difference in expression of PD-1, V-EGF, and AFP between ALPPS, PVE, and UH. CONCLUSIONS: ALPPS conferred a higher resection rate in hepatitis-related HCC with comparable short- and long-term oncological outcome with PVE.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Chan A, Zhang WY, Chok K, et al. ALPPS Versus Portal Vein Embolization for Hepatitis-related Hepatocellular Carcinoma: A Changing Paradigm in Modulation of Future Liver Remnant Before Major Hepatectomy. Ann Surg. 2021. PMID: 31305284. doi:10.1097/SLA.0000000000003433

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。